Mesa Laboratories INC /CO/ Form 4 insider transactions

Mesa Laboratories Inc. reports a Form 4 filing detailing the sale of common stock by SVP Operations Brian Archbold.

Mesa Laboratories CAO Lyndsey Crennen sold 118 shares of common stock to cover taxes on vested RSUs, with the transaction occurring on June 16, 2026.

Mesa Laboratories CFO John Sakys sold 1,223 shares of common stock to cover taxes related to RSU vesting, while also reporting indirect beneficial ownership of 50 shares held for his children.

Brian Archbold, SVP Operations at Mesa Laboratories Inc., reported a transaction involving the sale of common stock and the acquisition of Restricted Stock Units.

Mesa Laboratories CFO John Sakys reported transactions involving common stock, stock options, and restricted stock units.

Mesa Laboratories Inc. reports that President and CEO Siddhartha Kadia acquired 35,236 Restricted Stock Units (RSUs) on April 14, 2026.

Mesa Laboratories Inc. (MLAB) President and CEO Siddhartha Kadia acquired 34,807 Restricted Stock Units (RSUs) on April 14, 2026.

Mesa Laboratories President and CEO Gary M. Owens reported the forfeiture of 8,211 restricted stock units.

Mesa Laboratories Director John James Sullivan reported gifting 2,000 shares of common stock to a spousal lifetime access trust.

Mesa Laboratories President and CEO Gary M Owens acquired 11,558 shares of common stock through the vesting of performance share units.

A director at Mesa Laboratories reported changes in their beneficial ownership, including the vesting and acquisition of restricted stock units.

Mesa Laboratories Director John Sullivan reported the vesting of 1,404 restricted stock units and the grant of 2,784 new units, alongside changes in direct and indirect common stock holdings.

Mesa Laboratories Director Shannon Hall acquired 1,404 shares of common stock through the vesting of restricted stock units and was granted 2,784 new RSUs.

Mesa Laboratories Director R Tony Tripeny reported the vesting of 1,404 restricted stock units and the grant of 2,784 new units.

Mesa Laboratories Director Mark Capone saw 1,404 Restricted Stock Units vest and received a new grant of 2,784 RSUs.

Mesa Laboratories Director Jennifer Alltoft reported the vesting of 1,404 restricted stock units and the grant of 2,784 new restricted stock units.

Mesa Laboratories CFO John Sakys reported the acquisition of 1,036 common shares through RSU vesting and the disposition of 454 shares for tax purposes, increasing his direct beneficial ownership to 15,044 shares.

Mesa Laboratories' SVP of Operations, Brian David Archbold, exercised 844 Restricted Stock Units, acquiring common stock, and subsequently sold a portion to cover tax obligations.

Mesa Laboratories, Inc. CEO Gary Owens filed a Form 4 detailing the exercise of restricted stock units and subsequent sale of shares to cover tax obligations.

Mesa Laboratories President and CEO Gary Owens reported the acquisition of 8,707 shares of common stock through RSU conversion and the subsequent disposition of 3,810 shares for tax purposes on June 18, 2025.

Brian David Archbold, SVP Operations at Mesa Laboratories Inc., reported the future acquisition of 2,556 shares of common stock and the vesting of Restricted Stock Units on June 18, 2025, alongside a disposition of shares for tax purposes.

Mesa Laboratories' Chief Financial Officer, John Sakys, reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Mesa Laboratories, Inc. CFO John Sakys has been granted 8,133 Restricted Stock Units (RSUs) as part of his compensation, vesting over three years.

Mesa Laboratories, Inc. (MLAB) announced that Brian David Archbold, SVP Operations, was granted 7,346 Restricted Stock Units (RSUs) as part of his compensation, vesting over three years.

Mesa Laboratories' President and CEO, Gary M. Owens, reported the acquisition of 24,659 Restricted Stock Units (RSUs) on June 15, 2025, as part of a pre-arranged plan.

Mesa Laboratories' President and CEO, Gary M. Owens, reported the acquisition of shares through RSU vesting and performance share units, followed by a sale of shares to cover income tax obligations.

Mesa Laboratories' SVP of Operations, Brian Archbold, reported the acquisition of shares through RSU and performance share unit vesting, followed by a sale of a portion of his common stock holdings.

Mesa Laboratories CFO John Sakys filed a Form 4 detailing the acquisition of shares through RSU vesting and performance share units, alongside a sale of common stock.

Mesa Laboratories' Chief Financial Officer, John Sakys, filed a Form 4 disclosing the expiration of 4,087 unexercised non-qualified stock options on June 10, 2025.

Mesa Laboratories' SVP of Operations, Brian David Archbold, reported the expiration of 2,129 unexercised non-qualified stock options on June 10, 2025.